Emilie Toresson Grip

Publications
Public outreach and news

Articles

Article: DIABETES CARE. 2024;47(6):978-985
Metabolic Syndrome Traits Increase the Risk of Major Adverse Liver Outcomes in Type 2 Diabetes
Shang Y; Grip ET; Modica A; Skroder H; Strom O; Ntanios F; Gudbjornsdottir S; Hagstrom H
Article: GUT. 2024;73(5):835-843
Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes
Wester A; Shang Y; Grip ET; Matthews AA; Hagstrom H
Article: JOURNAL OF DIABETES RESEARCH. 2024;2024:6142211
Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study.
Langslet G; Nyström T; Vistisen D; Carstensen B; Grip ET; Casajust P; Tskhvarashvili G; Hoti F; Klement R; Karlsdotter K; Tuovinen M; Ofstad AP; Lajer M; Shay C; Koeneman L; Farsani SF; Niskanen L; Halvorsen S
Article: SCANDINAVIAN JOURNAL OF PAIN. 2023;23(4):694-704
Economic burden of osteoarthritis - multi-country estimates of direct and indirect costs from the BISCUITS study
Hallberg S; Rolfson O; Karppinen J; Schiottz-Christensen B; Stubhaug A; Toresson Grip E; Robinson RL; De Geer A; Schepman P
Article: SCANDINAVIAN JOURNAL OF PAIN. 2023;23(2):353-363
Problematic opioid use among osteoarthritis patients with chronic post-operative pain after joint replacement: analyses from the BISCUITS study
Hansen JL; Heilig M; Kalso E; Stubhaug A; Knutsson D; Sandin P; Dorling P; Beck C; Grip ET; Blakeman KH; Arendt-Nielsen L
Article: SCANDINAVIAN JOURNAL OF PAIN. 2023;23(1):126-138
Burden of disease and management of osteoarthritis and chronic low back pain: healthcare utilization and sick leave in Sweden, Norway, Finland and Denmark (BISCUITS): study design and patient characteristics of a real world data study
Hallberg S; Rolfson O; Karppinen J; Schiottz-Christensen B; Stubhaug A; Fischer MR; Gerdle B; Grip ET; Gustavsson A; Robinson RL; Varenhorst C; Schepman P
Article: DIABETES OBESITY & METABOLISM. 2023;25(1):261-271
Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase-4 inhibitors: Real world evidence from the Nordic EMPRISE study
Nystrom T; Toresson Grip E; Gunnarsson J; Casajust P; Karlsdotter K; Skogsberg J; Ustyugova A
Article: INTERNATIONAL UROGYNECOLOGY JOURNAL. 2021;32(11):3007-3015
Association between surgical volumes and real-world healthcare cost when using a mesh capturing device for pelvic organ prolapse: A 5-years comparison between single- versus multicenter use
Morcos E; Falconer C; Grip ET; Geale K; Hellgren K; Poutakidis G; Altman D
Journal article: VALUE IN HEALTH. 2020;23:s597
PMS26 BISCUITS - a large Nordic cohort study assessing burden, outcomes, and disease management for patients with osteoarthritis and chronic low back pain: Patient characteristics and prevalence in Sweden
Hallberg S; Rolfson O; Karppinen J; Schiøttz-Christensen B; Stubhaug A; Grip ET; Gustavsson A; Robinson RL; Varenhorst C; Emir B; Schepman P
Article: DIABETES CARE. 2019;42(4):545-552
Real-World Costs of Continuous Insulin Pump Therapy and Multiple Daily Injections for Type 1 Diabetes: A Population-Based and Propensity-Matched Cohort From the Swedish National Diabetes Register.
Toresson Grip E; Svensson A-M; Miftaraj M; Eliasson B; Franzén S; Gudbjörnsdottir S; Steen Carlsson K

All other publications

Letter: JOURNAL OF HEPATOLOGY. 2025;83(2):e95-e97
Potential issues with implementation of EASL-EASD-EASO guidelines on management of MASLD in patients with type 2 diabetes in Sweden
Roeren M; Grip ET; Skroder H; Shang Y; Hagstrom H
Conference publication: HEPATOLOGY. 2022;76:S620-S621
ADDITIONAL COMPONENTS OF THE METABOLIC SYNDROMES INCREASE THE RISK FOR SEVERE LIVER DISEASE IN PATIENTS WITH TYPE 2 DIABETES IN A DOSE-DEPENDENT MANNER
Shang Y; Toresson-Grip E; Ntanios F; Modica A; Strom O; Hagstrom H
Meeting abstract: DIABETES. 2018;67
Cost-Effectiveness of Once-Weekly Semaglutide 1.0 mg vs. Dulaglutide 1.5 mg as Add-On to Metformin in the Treatment of Type 2 Diabetes in Canada
Johansen P; Hakan-Bloch J; Liu AR; Persson S; Grip ET

Articles

All other publications

News from KI

Events from KI